The Adalimumab Biosimiliar Pipeline: What's Ahead
FDA approvals of these biosimilars started in 2016, but only 1 such product has successfully launched.
Daily Derm Times: May 14, 2025
Recludix Unveils First BTK SH2 Domain Inhibitor
AbbVie and ADARx Join Forces to Advance Next-Generation siRNA Therapies
Quoin Announces Positive QRX003 Data for Pediatric Peeling Skin Syndrome